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pneumonia, pulmonary hypertensive crisis with cardiac arrest, 
phrenic nerve palsy, and even death.(2,4,10) In South Africa, and 
especially in our centre, access to surgery is also dependent on 
finite resources such as beds in the intensive care setting and 
available theatre time.
The concept of transcatheter device closure for the treatment 
of cardiac defects has been recognised since the 1960s, with 
significant development of the procedure taking place over the 
last 2 decades.(1,2,10) The development and introduction of the 
Amplatzer device (St Jude Medical) (first described in 2002),(3) 
including muscular and perimembranous occluders, has made 
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Ventricular septal defects (VSDs) account for 20% - 40% of all 
cardiac lesions in the paediatric population.(1-9) Perimembranous 
VSDs (PMVSDs) are anatomically related to the aortic and 
tricuspid valves and are found in the upper part of the ventricular 
septum. PM VSDs make up 60% - 70% of all VSDs.(2,13)
Closure of a persistent, significant VSD is necessary, as volume 
overload of the left atrium and ventricle predisposes the patient 
to ventricular dilatation and dysfunction, arrhythmias, aortic 
regurgitation, pulmonary arterial hypertension, endocarditis, or 
a double-chambered right ventricle.(5,10) In addition, patients 
have a tendency to have frequent respiratory tract infections 
and failure to thrive where a VSD is left unrepaired.(2)
Surgical closure is the gold standard for repair of the VSD. It is 
now a routine procedure, with minimal mortality,(2,3,5,6,9,10) and is 
supported by a large body of data.(2) However, it can be asso-
ciated with complications, largely associated with the need for 
cardiopulmonary bypass and sternotomy.(8,9) Such complica-
tions include residual VSD and the need for repeat surgery, 
complete atrioventricular block (CAVB), post pericardiotomy 
syndrome, wound infection, arrhythmias, neurologic complica-
tions following cardiopulmonary bypass, atelectasis, chylothorax, 
Background/Hypothesis: Ventricular septal defect (VSD) 
is the most common congenital cardiac lesion. Surgical 
closure is the gold standard, but in an isolated peri-
membranous ventricular septal defect (PMVSD), per-
cutaneous closure is an attractive alternative, parti-
cularly in a limited resource setting. Our experience 
suggests that percutaneous closure of a perimembra-
nous VSD, in the appropriately selected patient, is safe 
and effective.
Materials and methods: We performed a retrospective 
chart review of all children that underwent percuta-
neous closure of a PMVSD at Inkosi Albert Luthuli 
Central Hospital, from October 2010 until December 
2016. Patients that had percutaneous closure of any 
VSD other than PMVSD, including residual VSD post-
surgical closure, were excluded. 
Results: Fourty two patients were included in our retro-
spective analysis, 27 females and 15 males, with a mean 
age of 6 years 6 months (Range: 2 years 9 months - 15 
years 9 months). Mean follow-up was 2 years 3 months. 
Successful device delivery was achieved in 97.6%. A total 
of 30 patients (71.4%) had complete closure of their 
defect. Eleven (26.2%) patients had a residual but 
haemodynamically insignifi cant defect. Two patients 
had mild aortic regurgitation post procedure. Signifi -
cant early complications included 1 patient with 
moderate tricuspid regurgitation and 2 patients with 
device embolisation. In one of these patients, the 
embolised device was retrieved and replaced with a 
larger device. In the second patient, surgical retrieval 
and closure was required. No cases of heart block were 
recorded.
Conclusions: In our experience, percutaneous closure of 
a perimembranous ventricular septal defect in a child 













percutaneous closure of perimembranous VSDs (a more 
complex procedure) accessible to an increased number of 
patients.(2,10) Previously, patients with a distance of at least 5mm 
between the defect and the aortic valve were eligible for 
closure of the defect with a muscular occluder. However, the 
more recent availability of the perimembranous occluder 
allowed for percutaneous closure of perimembranous defects 
with only 1 - 2mm between the defect and the aortic 
valve.(10) There is also literature reporting the use of a patent 
ductus arteriosus (PDA) occluder device to close VSDs per-
cutaneously.(4,15)
The Paediatric Cardiology Department at Inkosi Albert Luthuli 
Central Hospital (IALCH) is located in Durban, South Africa. 
Due to resource limitations, the waiting list for surgery is long. 
Thus, in this particular setting, percutaneous closure is a very 
attractive and possibly a more cost-effective option.
The aim of this study was to determine the safety and efficacy 
of percutaneous closure of perimembranous ventricular septal 
defects in the cohort of children treated in this unit.
PATIENTS AND METHODS
We performed a retrospective chart review of all children that 
underwent percutaneous closure of PM VSD at our unit from 
October 2010 until December 2016. Patients that had per-
cutaneous closure of any VSD other than PMVSD, including 
residual VSD post-surgical closure, were excluded. Ethics 
approval was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal.
All patients with PMVSD were assessed clinically and with 
transthoracic echocardiography (TTE). Patients that presented 
with evidence of a significant left-to-right shunt, based on clin-
ical and echocardiographic criteria, were considered for VSD 
closure. A left-to-right shunt was considered significant clinically 
when there was cardiomegaly on chest X-ray, failure to thrive 
or frequent respiratory tract infections. Echocardiographic 
criteria for a significant left-to-right shunt included left atrial 
dilatation (LA:Ao ratio >1.4) and/or LV EDD measurement 
with a Z-score of more than +2SD for age. Patients with a 
weight under 10kg, with defects considered too large or too 
close to the aortic valve, were referred for surgery. In the same 
period, 184 patients with VSD underwent surgical closure at 
our centre.
Catheterisation standard procedure
Informed consent was obtained prior to cardiac catheterisation 
from the patient’s parent and/or guardian. Prophylactic anti-
biotics (cefazolin 25mg/kg/dose) were administered 1 hour 
before the procedure and this was followed up by 2 doses post 
procedure. The procedure, to date, has been performed under 
general anaesthesia. After puncture of the femoral vessels, 
heparin 100IU/kg was given (max 5000IU) and the activated 
clotting time (ACT) was monitored regularly throughout the 
procedure. We aimed to keep the ACT at between 200 and 
300 seconds during the procedure. 
Fluoroscopy, transoesophageal as well as transthoracic echo-
cardiography were used. Characteristics of the VSD and relating 
aorta were assessed using standard right and left cardiac 
catheterisation, standard left ventriculography and angiography, 
as well as transoesophageal echo. A device 1 - 2mm larger than 
the VSD diameter was selected.(2,10)
The VSD was crossed with an appropriate catheter from the 
arterial side – usually a Judkins Right coronary catheter with an 
angled Terumo wire. If the strategy was to close the VSD 
retrogradely, as may be the case with some of the Amplatzer 
Duct Occluder (ADO) devices (ADO II) (St Jude Medical) and 
Amplatzer Muscular VSD occluders (St Jude Medical), the wire 
and catheter were placed in the pulmonary artery. However, if 
the plan was to deliver the device through the vein, then an 
arteriovenous circuit was created. An exchange length wire, 
usually a Noodle Wire (St Jude Medical) was passed through 
the catheter. A snare was used to capture the wire through an 
appropriate catheter placed in the femoral vein. The snared 
wire was then exteriorised from the femoral vein, creating an 
arteriovenous loop. More recently, an alternate method with 
the VSD crossed from the venous side directly, has been 
employed where possible. An appropriate delivery sheath was 
then introduced from the venous side and passed through the 
VSD over the guidewire and ideally placed in the LV or 
alternatively in the aorta. The guidewire was then removed and 
the occluder attached to a delivery wire, which was then passed 
through the sheath and deployed over the defect. The position 
of the device was assessed using echocardiography and fluoro-
scopy. The aortic and tricuspid valves, in particular, were 
carefully assessed for worsening regurgitation. When the device 
position was considered to be stable and satisfactory, it was 
released. 
All patients were transferred back to the ward post procedure, 
and were monitored overnight. A repeat 12-lead ECG, chest 
X-ray, echocardiogram and urine analysis (to check for signs of 
haemolysis) were done on the day after the procedure and 
were analysed on the same day. Aspirin 3 - 5mg/kg daily was 
started after the procedure and was continued for 6 months 
post device closure. After discharge, patients were followed up 
in our clinic at 4 - 6 weeks post procedure, and then 6 monthly 
to yearly thereafter if stable. At each follow-up visit, a clinical 
assessment, chest X-ray, ECG and transthoracic echo was done. 
ECGs were evaluated at the time of the visit and the standard 
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procedure is to record rate, rhythm, QRS axis, PR interval and 
signs of atrial enlargement or ventricular hypertrophy and any 
arrhythmias for each ECG done.
Devices
Devices used included ADO I and II, as well as the Amplatzer 
Membranous and Muscular VSD occluders (St Jude Medical) – 
see Figure 1. Selection of the device was based on the anatomy 
of the VSD and the distance from the aorta. 
RESULTS
Patients
Forty two patients were included in our retrospective analysis. 
In 41, the indication for PM VSD closure was a significant left-
to-right shunt. One had closure because of a preceding episode 
of infective endocarditis with significant tricuspid regurgitation 
(TR) due to a vegetation. 
Twenty seven patients (64.3%) were female and the mean age 
for our cohort was 6 years 6 months (Range: 2 years 9 
months - 15 years 9 months). The lowest weight was 11.4kg, 
with a median weight of 20.05kg. Table I delineates patient 
data with the relevant ranges.
Associated syndromes were Pena Shokeir syndrome in 1 
patient and Down’s syndrome in 2. One patient had moderate 
mitral regurgitation (MR) prior to PMVSD closure due to 
Double orifice mitral valve. The MR remained unchanged post 
PMVSD closure.
Cardiac catheterisation
Femoral venous and arterial access was used in all 42 patients. 
In 31 patients (73.8%) an arteriovenous loop was created to 
deliver the device. The ADO I device was the most common 
device used for percutaneous closure in 21 of the 42 patients 
(50%), followed by a membranous occluder, ADO II and 
muscular occluder (Table II). We used angiography and echo-
cardiography in all patients to determine a stable device posi-
tion before release. Three patients underwent combined pro-
cedures, 2 patent ductus arteriosus (PDA) closure with a coil, 
and 1 patient closure of a secundum atrial septal defect (ASD). 
More than 1 ventricular septal defect was present in 10 patients. 
In each case the larger defect was closed. A total of 30 
patients (71.4%) had complete closure of their defect. Eleven 
(26.2%) patients had a residual but haemodynamically insigni-
ficant defect. Of these, 8 patients were noted to have more 
than one VSD at the time of percutaneous closure.
Fluoroscopy time, procedural time (from time of induction of 
anaesthesia), dose of radiation, and amount of contrast used 
are summarised in Table III. 




Age (years), mean (range) 6.6 (2.8 - 15.8)
Weight (kg), mean (range) 20.4 (11.4 - 41.6)
Height (cm), mean (range) 114.8 (87 - 163)
Body Surface Area (m2), mean (range) 0.80 (0.52 - 1.37)
TABLE III: Procedural data as median (range).
Procedure time (min) 130 (55 - 360)
Fluoroscopy time (min) 29.05 (8.13 - 169.40)
Radiation dose (uGym2) 3862.65 (270.62 - 22029.20)
Contrast used (ml) 80.0 (28.0 - 170.00)
Contrast/kg body weight (ml/kg) 4.35 (1.37 - 7.83)
FIGURE 1: Devices used. 
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ID Weight* Device Used Size Method Outcome Early complications
Late 
Complications
1 22.90 Amplatzer Duct occluder II 5x4 AV Loop Residual VSD Moderate TR
2 27.10 Muscular occluder 10 AV Loop Residual VSD
3 21.70 Membranous occluder 8 AV Loop Closed
  4** 14.70 Muscular occluder 14 AV Loop Closed
5 14.80 Membranous occluder 8 AV Loop Closed
6 22.40 Membranous occluder 9 AV Loop Closed
7 18.70 Amplatzer Duct occluder I 8x6 AV Loop Closed Moderate AR
8 34.40 Muscular occluder 8 AV Loop Residual VSD
  9** 11.70 Amplatzer Duct occluder II 4x4 Arterial Residual VSD
10 30.40 Amplatzer Duct occluder II 12x10 Arterial Closed
11 23.40 Membranous occluder 8 AV Loop Closed
12 20.80 Amplatzer Duct occluder I 10/8 AV Loop Closed
13 23.00 Membranous occluder 10 AV Loop Closed
14 19.20 Amplatzer Duct occluder I 10/8 AV Loop Closed
15 20.90 Membranous occluder 6 AV Loop Closed
16 31.00 Membranous occluder 6 AV Loop Closed
17 26.60 Membranous occluder 11 AV Loop Closed
18 11.60 Amplatzer Duct occluder II 6/4 AV Loop Closed
19 15.00 Membranous occluder 9 AV Loop Closed
20 28.00 Membranous occluder 7 AV Loop Closed
21 19.50 Amplatzer Duct occluder I 10/8 AV Loop Closed
Device 
embolisation
22 17.50 Membranous occluder 10 AV Loop Closed
23 24.00 Amplatzer Duct occluder I 10/8 AV Loop Residual VSD
24 16.30 Amplatzer Duct occluder I 12/10 AV Loop Closed
  25** 21.00 Membranous occluder 7 AV Loop Closed
26 19.70 Amplatzer Duct occluder I 12/10 AV Loop Closed
27 21.40 Amplatzer Duct occluder I 8/6 AV Loop Closed
28 32.00 Membranous occluder 8 AV Loop Residual VSD
29 41.60 Amplatzer Duct occluder I 8/6 AV Loop Residual VSD
30 16.60 Amplatzer Duct occluder I 10/8 AV Loop Closed
31 22.00 Amplatzer Duct occluder I 8/6 AV Loop Closed
32 16.20 Amplatzer Duct occluder I 8/6 AV Loop Closed
33 20.40 Amplatzer Duct occluder II 5/6 Arterial Closed
34 14.10 Amplatzer Duct occluder I 10/8 AV Loop Residual VSD
35 21.20 Amplatzer Duct occluder I 8/6 Venous Residual VSD
36 11.40 Amplatzer Duct occluder I 8/6 Venous Closed
37 13.20 Amplatzer Duct occluder I 8/6 Venous Residual VSD
  38** 17.00 Amplatzer Duct occluder I 10/8 Venous Closed
39 13.80 Amplatzer Duct occluder I 8/6 Venous Closed
40 12.70 Amplatzer Duct occluder I 8/6 Venous Residual VSD
41 12.80 Amplatzer Duct occluder I 8//6 Venous Failed
Device 
embolisation
42 13.00 Amplatzer Duct occluder I 8/6 AV Loop Closed
TABLE 1I: Overview of device used, size, method and outcome.
*Weight in kilograms, **Follow-up <1 year, AV = arteriovenous, Residual VSD = haemodynamically insignificant residual VSD.
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Complications
One patient had elevated ST segments on electrocardiogram 
(ECG) after the sheath was placed across the VSD. There were 
no changes in blood pressure or heart rate and no pericardial 
effusion on the TOE. A coronary angiogram was done that 
demonstrated normal coronaries and the cause for this change 
in ST segments remains unclear. The patient’s subsequent ECGs 
demonstrated sinus rhythm with normal ST segments.
Another patient had a transient nodal rhythm after the 
sheath was placed across the VSD. This resolved sponta-
neously without any intervention or change in haemodynamic 
parameters. 
Only one patient had transient pulse loss post percutaneous 
VSD closure. Enoxaparin was administered and the pulse 
recovered within a few hours. There were no incidences of 
bleeding or haematoma reported.
Significant complications were documented in 3 patients. 
One had moderate tricuspid regurgitation post device closure, 
and 2 had device embolisation. In one of these patients, the 
embolised device (ADO II) was retrieved and replaced with a 
larger device (ADO I). In the second patient, device embolisa-
tion (ADOI) was detected on clinical review the morning 
following the procedure, and attempts at retrieval in the cardiac 
catheterisation laboratory were unsuccessful. This patient 
underwent surgical retrieval of the occluder from the left 
pulmonary artery followed by VSD closure. The patient had an 
uneventful post-operative course and was discharged within 8 
days of the initial percutaneous procedure. The index case with 
moderate TR post procedure had complete resolution of the 
TR at the latest follow-up visit. 
Two patients had mild aortic regurgitation (AR) post procedure. 
In 1 of these patients there appears to have been progression 
of the AR after 5 years, with some concern that the device was 
impinging on the right coronary cusp – a finding not appreciated 
immediately post procedure. The other patient has had no 
progression of the initial AR. Both patients remain under close 
follow up. 
No cases of heart block or significant arrhythmias were 
recorded.
Hospital stay post procedure
Thirty one patients were discharged the day following the 
procedure (range 1 day - 11 days, median 1 day) and 92.7% 
(38/41) of the cohort were discharged within 3 days of the 
procedure. In that group of patients, the reason for later dis-
charge related to difficulty with transportation. One patient 
stayed for 8 days post procedure, as she was from a very rural 
part of the country with limited access to healthcare. Another 
patient was found to have bilateral hydronephrosis on routine 
screening of the kidneys post procedure, and was kept in 
hospital for 11 days post PMVSD closure for a renal diagnostic 
work up. 
Follow up
All patients attended at least 1 post-procedural follow-up visit 
and the mean follow-up time was 2 years 3 months (n=42).
In terms of arrhythmias, 1 patient had a wandering atrial pace-
maker noted on her first follow-up ECG, and 1 patient had a 
first degree heart block (PR interval 0.24 s). Both of these 
subsequently resolved.
Several patients with mild to moderate MR and TR prior to 
PM VSD closure showed resolution of their valve regurgitation 
on follow-up. The patient that had previous infective endo-
carditis (IE) and a vegetation on the tricuspid valve causing 
severe TR, had persistent TR post PMVSD closure.
Four patients were lost to follow-up before 1 year. At last post-
procedural visit (range 1 - 16 weeks (n = 4)), 1 patient had 
residual flow through the device and the remaining 3 had 
complete closure of their VSDs. 
DISCUSSION
Studies reviewing percutaneous closure of PMVSDs report 
successful closure rates of 90% - 100%,(2,6,10) rates that are com-
parable with those achieved by surgical closure.(3,9)
Reported major complication rates for percutaneous closure 
are 0% - 8.6%.(15) The main complication for consideration was 
that of complete atrioventricular node block (CAVB) (0% - 
5.7%), a complication also associated with surgical repair of 
PMVSD (1% - 5%).(2,9,10) CAVB is associated with both per-
cutaneous and surgical repairs of this defect, due to the 
anatomical association between the conduction system and the 
defect.(2,10,12) The AV node is found in the posterior upper 
membranous ventricular septum and branches into the left and 
right bundle in the posterior lower margin.(4) Postulated 
mechanisms of interference include direct compression or 
inflammation of, or scar tissue formation within the conduction 
tissue.(2) In percutaneous device closures, CAVB tends to occur 
more frequently,(7) at a later stage, and in a less predictable 
fashion(10) when compared to surgery. Young age at time of 
implantation, specifically age less than 6 years, has been 
identified as the primary risk factor in some studies.(10) Similarly, 
various studies reported use of the Amplatzer PMVSD occluder 
as a common factor in patients presenting with early and late 













CAVB.(10,16,17) After these reports and further case reports of 
late CAVB associated with this device, a decision was made in 
our centre, in 2013, to discontinue use of the membranous 
occluder for percutaneous VSD closure.
No cases of CAVB were reported in our review. Late CAVB 
has been described 3 - 5 years post device closure(15) and 10 of 
the patients included in our review had not completed 3 years 
of follow-up visits. Due to the relatively small cohort size, it is 
impossible to speculate whether device size or type influenced 
the absence of CAVB. 
In a study by Oses, et al., patients were followed up for 4 years. 
Late onset of CAVB was not identified and QRS intervals 
remained constant. Of concern was that the PR interval 
increases with time. This finding has been flagged for ongoing 
monitoring and follow-up.(11) In that particular study, the 
Amplatzer VSD occluder was used and there was no incidence 
of CAVB in the patients with a prolonged PR interval after 4 
years of follow up.(11) 
In our cohort, 1 patient was noted to have a prolonged PR 
interval 2 years 7 months post procedure (PR interval of 240ms 
at age 15 years). Fortunately, this has resolved, and his PR 
interval has remained at 0.2 seconds. No other significant 
rhythm abnormalities were reported in our review.
Other recognised complications of percutaneous perimem-
branous VSD closure include other rhythm abnormalities (atrial 
fibrillation, bundle branch blocks), device embolisation, and 
vascular complications (for example, femoral arterial throm-
bosis).(2,11) New valve regurgitation or significant residual shunts 
have not generally been identified as problematic in some 
studies;(2) however, aortic and/or tricuspid insufficiency and 
residual shunts have been cited as potential complications in 
other reviews.(7,9) Other studies have identified serious com-
plications such as perihepatic bleeding, cardiac perforation, 
rupture of tricuspid valve chordae tendineae, and procedure-
related death.(2,4) The surgical approach is associated with a 
higher complication rate. However, many of these are minor 
(i.e. complications not requiring treatment, including small 
pneumothoraces or small pleural effusions).(3,9) 
For the patient, percutaneous VSD closure has considerable 
benefit, including less psychological impact due to absence of a 
surgical scar, no need for intensive care admission, less pain, and 
shorter time in hospital.(2,10)
When comparing percutaneous vs. surgical closure, it is 
important to note the difference in the patients selected for 
each treatment option. The patient profiles are significantly 
different and this should be considered when interpreting 
outcomes and complications of these 2 groups of patients. 
Patients suitable for device closure tend to be older (with 
correspondingly higher weights), with smaller VSDs, and no 
associated cardiac defects that require surgical intervention.(9)
Complications included device embolisation in 2 patients. 
Retrospectively, both instances of embolisation could have 
been prevented with a more appropriately sized device, as pre-
viously reported.(10,14,15)
Valve regurgitation is a complication noted in various re-
ports.(2,7,9,10-16) If significant AR occurs during the procedure, the 
procedure is usually abandoned (unless the device can be 
repositioned to abolish AR) and the patient referred for sur-
gical closure. None of our patients had new onset AR during 
the procedure. However, 2 of our patients had new onset AR 
the day after the procedure, both classified as mild. Some 
reports mention trivial to mild post-procedural AR occurring 
in up to 3.0% of patients(2,7,16) and suggest that there is no 
progression of this regurgitation during follow-up.(2,14,16) In 1 
patient from our cohort, the AR remained mild and asymp-
tomatic. However, in the other, there has been apparent 
progression at 5 years and 11 months post procedure. This may 
suggest that mild valve regurgitation could progress in patients 
where the device is in very close proximity to the aortic valve; 
any degree of neo-AR is, therefore, unacceptable. 
One patient developed moderate TR the day after the 
procedure and was evaluated with TTE for any chordal injury. 
This was excluded, and, on follow-up, the TR resolved.
Closure rates post percutaneous closure vary according to 
what definition is used and a distinction is made between 
complete closure and successful closure.(11,14) At the time of our 
study, 71.42% (30/42) of patients were classified as having 
complete closure. Complete closure is reported to be 71% - 
100%.(2,5,8,10,15,16) Eleven patients had a residual but haemo-
dynamically insignificant shunt. Spontaneous closure is still a 
possibility, as is readmission for closure of remaining defects 
percutaneously, should this be indicated. One patient included 
in the group with residual defects had a small leak through the 
device initially, but was subsequently lost to follow-up. 
Studies that report on successful percutaneous closure define 
this as device placement in the correct position, with no 
significant complications (valve regurgitation) or a significant 
shunt that requires surgical closure.(16) If we use that as a 
measure of outcome in our review, the success rate is 97.6% 
(41/42), similar to other reports.(2,5,8,10,15,16)
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Limitations of the study include the limited follow-up period, 
the relatively small number of patients, and the significant 
number of patients who had defaulted follow-up.
CONCLUSION
Percutaneous closure of perimembranous ventricular septal 
defects in children appears to be safe and effective. Evaluation 
over a longer period of time is, however, still necessary. 
Improvement in device design may be important in pre-
venting complications related to conduction defects and valve 
regurgitation.
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